The United Kingdom and the United States have signed a landmark bilateral deal that will keep no levies on UK pharmaceutical products going into the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has pledged to raise expenditure on pharmaceuticals through the NHS. This pledge ensures that duties on these key products will be held at zero for a duration of the next three years.
This agreement comes after previous warnings to hike duties on branded pharmaceutical imports, with potential rates floated as high as one hundred percent.
"This agreement between the Britain bolsters the worldwide climate for innovative medicines and brings much-needed fairness to transatlantic pharmaceutical trade," a release declared.
Commercial Impact
Drugs are one of the UK's largest export categories to the US, which is by far the primary destination for leading companies like GSK and AstraZeneca.
Statistics show that in the 12 months prior to last September, the UK sold pharmaceutical products valued at over eleven billion pounds to the US. This value made up nearly one-fifth of total UK exports in that span.
"This guarantee protects employment, stimulates funding and paves the way for the UK to establish itself as a international leader for medical research," the Business and Trade Secretary stated.
Specific UK Commitments
The deal includes several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will raise the price threshold at which it considers new treatments to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a goal to raise overall NHS spending on medicines from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The sum drug companies must return to the NHS to prevent overspending will be capped at fifteen percent. Last year, repayments were more than 20%.
Recent Tensions
This agreement follows a long-running tension between the sector and the ministers over medicine costs and regulatory access.
These tensions were intensified by assertions that US consumers were charged several times more for the identical medicines than consumers in the UK and Europe.
In recent months, several significant manufacturing plans in the UK have been delayed or cancelled, while major funding commitments have been directed toward US facilities.
The Science Minister stated that the NHS must invest a greater share on treatments, noting that its budget allocation on drugs had declined as a percentage of its overall budget over the past decade.
